GSK Leverages Higher Return On OTC R&D Investment To Drive Growth – Witty
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline will be investing more R&D dollars in its consumer health care business, where spending on innovation pays off more quickly and more consistently than in the prescription sector, CEO Andrew Witty says
You may also be interested in...
NanoBio's OTC Route For Cold Sore Med Pays Off With GSK Deal
Privately held biotech company NanoBio's novel cold sore treatment is deviating from the Rx market path most new molecules follow by aiming straight for the OTC market with the help of GlaxoSmithKline
NanoBio's Decision To Go OTC With Its Cold Sore Med Pays Off With GSK Deal
The privately-held biotech chooses a different commercial path for its proprietary product and gains validation for its nano-emulsion delivery platform, NanoStat.
GSK Plans To Wield Aggressive Bolt-On Acquisition Strategy
GlaxoSmithKline is planning on moving aggressively beyond its core prescription drug business with possible bolt-ons in consumer health among other categories, CEO Andrew Witty told investors at a recent Goldman Sachs conference in New York